netFormulary NHS
Pan Mersey
Area Prescribing Committee
 Search
 Formulary Chapter 29: STATIC LIST - Full Chapter
Notes:

Prescribing recommendations on the static list will only be reviewed if significant new evidence becomes available.

 Details...
29.01  Expand sub section  STATIC LIST | A B C
 note 

Red Traffic Light STATIC | Abatacept infusion and subcutaneous injection  (Orencia®▼) in rheumatological conditions

Red Traffic Light STATIC | ADALIMUMAB injection  (Humira®▼) in rheumatological conditions

Black Traffic Light STATIC | Antioxidant supplements for Age-Related Macular Degeneration

Green Traffic Light STATIC | BLOOD GLUCOSE TESTING STRIPS

Amber Initiated ARCHIVE | BRIVARACETAM tablets and oral solution  (Briviact®▼)

Red Traffic Light STATIC | CERTOLIZUMAB injection  (Cimzia®▼) in rheumatological conditions

Red triangle STATIC | CODEINE: USE IN CHILDREN

Amber Traffic Light STATIC | COLESEVELAM HYDROCHLORIDE  (Cholestagel®▼)

29.02  Expand sub section  STATIC LIST | D E F
 note 

Amber Retained ARCHIVE | DEGARELIX subcutaneous (SC) injection  (Firmagon®)

PDF document ARCHIVE | DIETARY CHOICES, Adults with particular

Red triangle STATIC | DOMPERIDONE: updated indications, dose and contraindications

Black Traffic Light STATIC | DOXAZOSIN modified release (M/R) tablets  (All Brands)

Red Traffic Light STATIC | ETANERCEPT injection  (including biosimilars) in rheumatological conditions

Green Traffic Light STATIC | FINASTERIDE 5mg tablets

29.03  Expand sub section  STATIC LIST | G H I
 note 

Black Traffic Light STATIC | GLUCOSAMINE and CHONDROITIN products

Red Traffic Light STATIC | GOLIMUMAB injection  (Simponi®▼) in rheumatological conditions

Red Traffic Light STATIC | INFLIXIMAB infusion  (including biosimilars) in rheumatological conditions

aAmber Traffic Light STATIC | IVABRADINE  (Procoralan®▼) for the treatment of chronic heart failure

Green STATIC | IVERMECTIN 10mg/g cream  (Soolantra®)

29.05  Expand sub section  STATIC LIST | M N O
 note 

GreenV2 Traffic Light STATIC | NALOXEGOL Tablets  (Moventig®▼)

Black Traffic Light STATIC | ORAL COMBINATION PRODUCTS  

29.06  Expand sub section  STATIC LIST | P Q R S to top
 note 

PDF document STATIC | Prescribing for patients living or travelling abroad or otherwise absent from the UK

Black Traffic Light STATIC | POTASSIUM HYDROXIDE 5% Solution  (MolluDab® or Molutrex®)

Black Traffic Light STATIC | PREDNISOLONE ENTERIC COATED tablets

Amber Initiated STATIC | QUETIAPINE Immediate Release I/R Tablets  (All Brands)

Amber Traffic Light STATIC | RIFAXIMIN 550mg tablets  (Targaxan®)

Red Traffic Light STATIC | RITUXIMAB infusion in Rheumatoid Arthritis (RA)

Amber Initiated Traffic Light STATIC | RIVAROXABAN 2.5mg tablets  (Xarelto®▼) for Acute Coronary Syndrome

Green Traffic Light STATIC | Rosuvastatin tablets

29.07  Expand sub section  STATIC LIST | T U V
 note 

Black Traffic Light STATIC | TAPENTADOL immediate release preparations  (Palexia®)

Red Traffic Light STATIC | TOCILIZUMAB  (RoActemra®) in rheumatological conditions

Red Traffic Light STATIC | USTEKINUMAB injection  (Stelara®) for Psoriatic Arthritis

 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Medicines considered suitable for non-specialist prescribing in primary or secondary care.  

Amber Recommended

Amber Recommended  

Amber Initiated

Amber Initiated. Requires specialist initiation of prescribing. Prescribing to be continued by the specialist until stabilisation of the dose is achieved and the patient has been reviewed. Amber Initiated medicines must meet criteria: (1) Requires specialist assessment to enable patient selection (2) Medicine is suitable for on-going prescribing in Primary Care (3) Requires short to medium term specialist prescribing and monitoring of efficacy or toxicity until the patientís dose and condition is stable   

Amber Retained

Amber Patient Retained. Requires specialist initiation of prescribing. Prescribing to be continued by specialist until stabilisation of the dose is achieved and the patient had been reviewed. Patient remains under the care of specialist (ie not discharged) as occasional specialist input may be required. Amber Patient Retained medicines must meet criteria: (1)Requires specialist assessment to enable patient selection (2)Medicine is suitable for on-going prescribing in Primary Care (3) Requires short to medium term specialist prescribing and monitoring of efficacy or toxicity until the patientís dose and condition is stable (4) May require occasional specialist input indefinitely and therefore the patient should not be discharged from specialist care   

Amber

Medicines recommended or initiated by specialists in primary or secondary care. Non-specialist prescribing in primary care may follow according the RAG criteria. In process of being superceded by Amber Recommended, Amber Initiated and Amber Patient Retained.  

Purple

Shared Care. Medicines are considered suitable for Primary Care prescribing and/or management, following specialist initiation of therapy, with on-going communication between the Primary Care prescriber and specialist, within the framework of a Shared Care Agreement. Medicines designated as requiring Shared Care require on-going input from both Specialist and Primary Care clinicians and patients should not be discharged from Specialist care. Where prescribing and monitoring are required under shared care, it is implicit that the responsibility for both of these tasks rests with the prescriber. A Shared Care Agreement will always be available for Shared Care medicines and this document will include a Shared Care Agreement pro-forma which will be completed by all involved clinicians. This pro-forma will record agreement to take on defined aspects of care e.g. monitoring and/or on-going prescribing for the individual patients. A policy detailing clinician responsibilities in Shared Care Agreements must be referred to in all cases of Shared Care. All drugs to be included in this category must meet Shared Care criteria 1 to 3: SC1 Requires specialist assessment to enable patient selection and also initiation, stabilisation and review of treatment and the patient`s condition. SC2 Prescribing and/or management of the drug in Primary Care with specialist support and input, within the framework of the Shared Care Agreement is safe and convenient and that there is an appropriate mechanism for individual patient access in Primary Care. SC3 Requires specific long-term monitoring (blood test or other measurement) for adverse effects and / or efficacy of the drug to be completed in Primary Care, and requires on-going specialist support for the dose changes or management of adverse effects. Monitoring is required on a regular basis (typically four times a year). Implicit in any shared care agreement is the understanding that participation is at the discretion of the Primary Care prescriber subject to their clinical confidence.   

Red

Primary care prescribing of these medicines is NOT recommended. These treatments should be initiated by specialists only; ongoing prescribing is retained within secondary care.   

Black

Not recommended for use. Deviation from the policy may be considered on an individual basis where exceptional circumstances exist.   

Grey

Not recommended for use at this time. Deviation from the policy may be considered on an individual basis where exceptional circumstances exist. Further guidance will be issued when more information or evidence is made available.  

netFormulary